

Formal syntheses of (–)- and (+)-aphanorphine from (2*S*,4*R*)-4-hydroxyproline

Zhiqiang Ma,^a Hanwei Hu,^a Wanting Xiong^a and Hongbin Zhai^{a,b,*}

^aThe Laboratory of Modern Synthetic Organic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China

^bThe State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 38 College Road, Beijing 100083, China

Received 19 March 2007; revised 30 April 2007; accepted 17 May 2007

Available online 21 May 2007


Abstract—We describe the efficient formal syntheses of both natural (–)-aphanorphine and unnatural (+)-aphanorphine from the same commercially available amino acid, (2*S*,4*R*)-4-hydroxyproline. The tricyclic framework was constructed by intramolecular Friedel–Crafts reaction. (1*R*,4*S*)-1-Methyl-8-methoxy-3-(4-toluenesulfonyl)-2,3,4,5-tetrahydro-1,4-methano-3-benzazepine (**8**) was synthesized in six steps from sulfonamide **3**; (–)-aphanorphine methyl ether **24** was obtained in seven steps from lactone **10**. Intramolecular etherification of **18** proceeded with excellent stereoselectivity in the presence of BF₃·OEt₂, which has paved an efficient synthetic route to a series of medicinally attractive heterocycles.

© 2007 Elsevier Ltd. All rights reserved.

1. Introduction

(–)-Aphanorphine [(–)-**1**, Scheme 1], a novel alkaloid isolated by Shimizu and Clardy from the freshwater blue-green alga *Aphanizomenon flos-aquae* nearly two decades ago,¹ has stimulated tremendous synthetic attention² owing to its potential biological activity and unique structure containing tricyclic 3-benzazepine framework that resembles benzomorphanes analgesics^{3,4} such as pentazocine. Although a number of synthetic strategies have been reported for natural (–)-aphanorphine, unnatural (+)-aphanorphine, and (±)-aphanorphine in the literature,² currently there still exists strong demand for developing simpler and more efficient synthetic approaches for these molecules for the purpose of biological studies. Our previous synthesis of (–)-aphanorphine^{2r} featured the formation of ring B at the final stage by Friedel–Crafts alkylative cyclization, while in most other strategies ring B was constructed prior to ring C. Moreover, carbohydrates,^{5a} terpenes,^{5b} and especially amino acids,^{5c} have been widely used in the total synthesis of natural products. As shown in Scheme 1, (2*S*,4*R*)-4-hydroxyproline (**2**) was considered as an excellent starting point to secure the advanced tricyclic intermediates for constructing both

enantiomers of aphanorphine, which would lead to novel, formal syntheses of (–)-aphanorphine and (+)-aphanorphine based on the ‘chiral pool’ strategy. Although we were not the first to ‘extract’ the chiron from **2** in the synthesis of aphanorphine, the previous approach^{2m} made use of an initial enolate benzylation of a derivative of **2** and decarboxylation at a later stage, which adversely affected the overall synthetic efficiency in terms of atom economy and stereoselectivity. Moreover, our present research should be of great significance in terms of diversity-oriented synthesis. Some preliminary results along this line have been reported by our laboratory.^{2s,y} Herein, we wish to describe the full account of our findings regarding the syntheses of natural (–)-aphanorphine and unnatural (+)-aphanorphine from (2*S*,4*R*)-4-hydroxyproline (**2**).



Scheme 1. Proposed synthesis of (–)- and (+)-aphanorphine.


Keywords: Alkaloid; Aphanorphine; Asymmetric synthesis; Configuration inversion; Intramolecular Friedel–Crafts reaction.

* Corresponding author. Tel.: +86 21 54925163; fax: +86 21 64166128; e-mail: zhaih@mail.sioc.ac.cn

2. Results and discussion

2.1. (A) Formal synthesis of (–)-aphanorphine: synthesis of **8** from **2**


As outlined in Scheme 2, the synthesis of (–)-aphanorphine ((–)-**1**) commenced from alcohol **3**, an intermediate⁶ obtainable from **2** in 72% yield by a four-step process. Swern oxidation^{7a} of **3** gave a crude aldehyde, which in turn was acylated⁸ with 4-methoxyphenylmagnesium bromide to furnish **4** in 91% yield as a single pure compound. Exposure⁹ of alcohol **4** to triethylsilane in the presence of $\text{BF}_3 \cdot \text{OEt}_2$ in dichloromethane produced **5** in high yield (95%), as a result of benzylic reductive dehydroxylation with concomitant O-desilylation. Oxidation^{7b} with IBX (i.e., *o*-iodoxybenzoic acid) of **5** afforded ketone **6** in 98% yield. Nucleophilic methylation of **6** with methylmagnesium iodide¹⁰ produced the tertiary alcohols **7a/7b** (equally utilizable, 78%). The diastereomeric ratio was measured by ¹H NMR integral analysis to be 4:1, presumably favoring **7a** based on steric consideration. By following the previously published protocol from this laboratory,^{2r} AlCl_3 -promoted Friedel–Crafts alkylative cyclization of alcohols **7a/7b** was effected to furnish the desired intermediate **8** as colorless needles (64%). The sample of **8** was in high enantiopurity (99.8% ee), as determined by HPLC analysis [Chiralpak AD column: 250×4.6 mm, UV detector: 254 nm, eluant: hexanes/2-propanol (4:1), flow rate: 0.7 mL/min], indicating that essentially no epimerization ever took place. The $[\alpha]_D^{20}$ of **8** was found to be -14.2 (*c* 0.93, CHCl_3) {lit.^{2r} $[\alpha]_D^{20} -13.4$ (*c* 0.969, CHCl_3)}. Other spectroscopic data of **8** were also in agreement with those disclosed in the literature.^{2r} Thus a new formal synthesis of alkaloid (–)-aphanorphine ((–)-**1**) has been completed, since **8** could further be manipulated to give (–)-**1** in three additional steps (desulfurization, N-methylation, and 8-O-demethylation).



Scheme 2. Synthesis of **8**.

2.2. (B) Formal synthesis of (+)-aphanorphine: synthesis of **24** from **2**

The synthesis of unnatural (+)-aphanorphine from (2*S*,4*R*)-4-hydroxyproline (**2**) featured configuration inversion at C-2 of the amino acid. Chemoselective N-benzoylation (BzCl , NaOH , Et_2O , 0 °C and then room temperature, 24 h, 76%) of **2** produced amide **9** (Scheme 3).^{11a} Agitation of **9** in acetic anhydride heated at 90 °C for 5 h effected the requisite lactonization and configuration inversion at C-2 in the same step to provide bicycle **10** in 90% yield, by taking advantage of an efficient protocol developed recently by Rosa and Croce.^{11b} Interestingly, treatment of sulfonamide **11**¹² (prepared in 83% yield by selective N-tosylation of **2** with TsCl in the presence of Na_2CO_3) with acetic anhydride at 90 °C for 8 h resulted only in the acylation of the secondary hydroxyl and the acetate **12** was obtained in 95% yield as a colorless solid. The desirable lactonization with configuration inversion at C-2 failed to take place just because the substituent on the nitrogen atom was switched from Bz (in **9**) to Ts (in **11**).



Scheme 3. Cyclization of **9**.

Treating¹³ a mixture of lactone **10** and $\text{Me}(\text{MeO})\text{NH} \cdot \text{HCl}$ (120 mol %) in tetrahydrofuran with *p*-methoxyphenylmagnesium bromide (370 mol %) at -10 °C furnished γ -hydroxy- α -amido ketone **14** (27%) along with diamide **13** (55%) and diol **15** (17%) (Scheme 4; Table 1, entry 1). The yield of **14** was increased to 41% when the reaction was run at -78 °C (entry 2). Since additional **14** could be formed from the Weinreb amide **13** in moderate yield (64%) by reacting with excess *p*-methoxyphenylmagnesium bromide (at -35 °C and then room temperature), phenyl ketone **14** could be obtained from lactone **10** in 76% overall yield. For comparison, direct addition of *p*-methoxyphenylmagnesium bromide (130 mol %) to lactone **10** at -78 °C (i.e., without the involvement of $\text{Me}(\text{MeO})\text{NH} \cdot \text{HCl}$) gave **14** in only 44% yield.

Ketone deoxygenation of **14** was then vigorously pursued (Scheme 5). Initially, a stepwise reduction strategy (i.e., via the benzylic alcohol intermediate) was explored. For instance, reduction of **14** with NaBH_4 ¹⁴ in MeOH at 0 °C for 1 h smoothly formed the diol **18** (88%) essentially as a single diastereomer (*dr*=70:1). The configuration of the newly generated stereocenter of this diol was assigned based on the Cram rule. To our surprise, exposure of **18** to triethylsilane in the presence of $\text{BF}_3 \cdot \text{OEt}_2$ in dichloromethane (at 0 °C and then room temperature) effected intramolecular etherification rather than benzylic reductive dehydroxylation. In


Scheme 4. Ring opening of **10**.

Table 1. Comparison of the results obtained under different temperatures

Entry	Me(MeO)NH·HCl (equiv)	PMPMgBr (equiv)	Temperature (°C)	Isolated yield (%)		
				13	14	15
1	1.2	3.7	−10	55	27	17
2	1.2	3.7	−78	55	41	4


contrast, dehydroxylation of **4** took place smoothly under the same condition, as mentioned above (Scheme 2). The hydroxyl at the C-4 of **18**, situating *cis* to the α -hydroxy PMB moiety on the pyrrolidine ring, rapidly captured the benzylic cation generated in the system before it was reduced by Et₃SiH. Bicyclic heterocycle **19** was produced (82%) as a pair of rotamers (1.3:1, deduced from the line integrals of ¹H NMR spectrum). Note that the benzylamine derivative **20**, obtained in 76% yield by reducing **19** with LiAlH₄ in refluxing THF, proved to be a single pure compound. The PMP substituents of **19** and **20** should occupy the *exo* position according to the NOESY experiments on **20**.


Obviously, BF₃·OEt₂ alone was responsible for the intramolecular etherification of **18** and Et₃SiH did not play any role here. Actually, trifluoroacetic acid (TFA) could also bring about the same intramolecular etherification of **18** although ether **19** was obtained in only 34% yield in this case. Next, we were pleased to reveal that exposure of **18** to triethylsilane in the presence of TFA (instead of BF₃·OEt₂) afforded **17** in 75% yield. Furthermore, bicycle **19**, inert to the BF₃·OEt₂/Et₃SiH system, could be converted to **17** in 61% yield through reductive ring opening upon treatment with

TFA and Et₃SiH. This method even proved to be successful in the case of ketone **14** itself acting as the substrate. Subjecting **14** to Et₃SiH¹⁵ in the presence of TFA produced **17** directly in one step (**17**: 62% and **14**: 13%; the yield of **17** was amounted to be 71% based on the recovered starting material). The remarkable difference between BF₃·OEt₂/Et₃SiH and TFA/Et₃SiH as reducing agent combinations should be noted.

In addition, alcohol **17** could be obtained from ketone **14** via 1,3-dithiolane formation (HSCH₂CH₂SH, BF₃·OEt₂, CH₂Cl₂, reflux, 80%),¹⁶ followed by desulfurization via a free-radical reaction (*n*-Bu₃SnH, AIBN, MePh, 90 °C; **17**: 73% and **14**: 15%; the yield of **17** was amounted to be 86% based on the recovered starting material).¹⁷

After alcohol **17** became easily accessible, we focused on completing the formal synthesis of (+)-aphanorphone (Scheme 6). Under the typical Swern condition, secondary alcohol **17** was oxidized to afford pyrrolidinone **21** in excellent yield (98%). Nucleophilic addition of methyllithium¹⁸ to ketone **21** (from the less hindered face) in tetrahydrofuran at −78 °C produced tertiary alcohol **22** in 39% yield (or 80% yield based on the recovered starting material) and in excellent stereoselectivity along with the recovered **21** (52%). The ¹H NMR of **22** showed two sets of peaks for some protons as a result of the presence of two rotamers in a ratio of 5:1. Reduction of **22** with lithium aluminum hydride in refluxing tetrahydrofuran gave the corresponding benzylamine, which displayed only one set of resonance signals in the ¹H NMR spectrum. Aluminum chloride^{2r} promoted intramolecular

Scheme 5. Synthesis of **17** and Cyclization of **18**. PMP=*p*-methoxyphenyl, Bz=benzoyl.



Scheme 6. Synthesis of **24**. PMP=*p*-methoxyphenyl, Bz=benzoyl.

Friedel–Crafts reaction of alcohol **22** took place at room temperature to generate the desired alkylative cyclization product **23** as a colorless oil (76%). Thus the tricyclic framework of aphanorphine was rapidly constructed from lactone **10**. Hydrolysis¹⁹ of **23** with 50% aqueous sodium hydroxide solution in refluxing ethanol, followed by N-methylation with formalin and sodium cyanoborohydride in methanol at room temperature, afforded (–)-aphanorphine methyl ether **24** in 71% overall yield for the two steps from **23**. The $[\alpha]_D^{28}$ of **24** was found to be -10.38 (*c* 1.36, CHCl₃) [lit.^{2a} $[\alpha]_D^{27}$ -7.40 (*c* 0.35, CHCl₃), lit.^{2v} $[\alpha]_D^{30}$ -9.72 (*c* 0.67, CHCl₃), lit.²ⁱ *ent*-**24** $[\alpha]_D^{21}$ $+10.4$ (*c* 1.24, CHCl₃)]. Other spectroscopic data of **24** were in accord with those reported previously.²¹

3. Conclusion

In summary, we have accomplished efficient syntheses of (1*R*,4*S*)-1-methyl-8-methoxy-3-(4-toluenesulfonyl)-2,3,4,5-tetrahydro-1,4-methano-3-benzazepine (**8**) in six steps from sulfonamide **3**, and of (–)-aphanorphine methyl ether **24** in seven steps from lactone **10**, both featuring an intramolecular Friedel–Crafts reaction for the construction of ring B. Both **3** and **10** were derived from the same commercially available amino acid, (2*S*,4*R*)-4-hydroxyproline (**2**). The present work constitutes efficient formal syntheses of both natural (–)-aphanorphine and unnatural (+)-aphanorphine. In addition, it is noteworthy that under similar conditions (BF₃·OEt₂/Et₃SiH and TFA/Et₃SiH) diol **18** underwent different reactions (intramolecular etherification and reduction, respectively), which would find applications in total synthesis of natural products. Especially, intramolecular etherification of **18** proceeded with excellent stereoselectivity in the presence of BF₃·OEt₂, which has paved an efficient synthetic route to a series of medicinally attractive heterocycles.

4. Experimental

4.1. General

Melting points were uncorrected. All solvents and reagents were obtained from commercial sources and used without further purification unless otherwise stated. NMR spectra were recorded in CDCl₃, D₂O, CD₃COCD₃, and DMSO-*d*₆ (¹H at 300 MHz and ¹³C at 75, 100, and 125 MHz) using TMS as the internal standard. Analytical samples were

obtained by chromatography on silica gel. Anhydrous solvents and reagents were obtained as follows: dichloromethane was distilled over calcium hydride under N₂; THF, ether, and toluene were distilled over sodium benzophenone ketyl under N₂.

4.1.1. Compound 4. To a solution of (COCl)₂ (2.60 mL, 30.3 mmol) in anhydrous CH₂Cl₂ (60 mL) was added dropwise a solution of DMSO (3.50 mL, 49.3 mmol) in CH₂Cl₂ (20 mL) at -78 °C under Ar. The mixture was stirred for 10 min and then a solution of **3** (7.47 g, 19.4 mmol) in anhydrous CH₂Cl₂ (20 mL) was introduced slowly. After the addition, the mixture was stirred for 0.5 h at -78 °C and Et₃N (15.0 mL, 108 mmol) was added. The dry-ice bath was removed and the mixture was allowed to warm up to room temperature over 10 min. After evaporation of the solvent, the mixture was dissolved in anhydrous THF (50 mL) under Ar. The THF solution was transferred to an addition funnel fitted to a three-necked flask charged with a solution of *p*-methoxyphenylmagnesium bromide in THF (50 mL) [prepared from *p*-methoxyphenyl bromide (12.0 mL, 95.9 mmol)]. The flask was cooled in a dry-ice/acetone bath. The solution of the aldehyde in THF (50 mL) was slowly added while the mixture in the reaction flask was vigorously stirred. After the addition, the reaction mixture was stirred at 0 °C for 3 h, quenched with saturated aqueous NH₄Cl solution, concentrated, and extracted with CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtered, and concentrated to give a residue, which was chromatographed (hexanes/EtOAc, 4:1) to afford adduct **4** (8.67 g, 91%) as a pale yellow syrup: ¹H NMR (300 MHz, CD₃COCD₃) δ 0.00 (s, 3H), 0.05 (s, 3H), 0.82 (s, 9H), 1.25–1.29 (m, 1H), 2.25–2.33 (m, 1H), 2.54 (s, 3H), 3.22 (dd, *J*=10.8, 4.2 Hz, 1H), 3.74 (ddd, *J*=10.8, 4.8, 1.8 Hz, 1H), 3.90 (s, 3H), 3.94–3.99 (m, 1H), 4.60–4.63 (m, 1H), 4.76 (dd, *J*=3.9, 2.1 Hz, 1H), 5.47 (br s, 1H), 7.04 (dd, *J*=8.7, 2.1 Hz, 2H), 7.46 (dd, *J*=8.7, 1.2 Hz, 2H), 7.55 (dd, *J*=7.8, 1.2 Hz, 2H), 7.94 (dd, *J*=7.8, 1.8 Hz, 2H); ¹³C NMR (75 MHz, CD₃COCD₃) δ -4.9 , -4.8 , 18.5, 21.4, 26.1, 34.6, 55.4, 58.2, 66.4, 71.1, 74.0, 114.3, 127.5, 128.6, 130.5, 135.0, 135.7, 144.2, 159.6; EIMS: *m/z* (%)=354 (100), 137 (41), 91 (35), 200 (27), 355 (26), 155 (21), 476 (1) [M–CH₃]⁺; Anal. Calcd for C₂₅H₃₇NO₅Si: C 61.07, H 7.58, N 2.85; found C 61.10, H 7.69; N 2.77.

4.1.2. Compound 5. A mixture of **4** (8.04 g, 16.4 mmol) and Et₃SiH (9.0 mL, 56 mmol) in CH₂Cl₂ (80 mL) was cooled to

0 °C by an ice/salt bath. To this cooled solution was added slowly a solution of $\text{BF}_3 \cdot \text{OEt}_2$ (9.0 mL, 71 mmol) in CH_2Cl_2 (30 mL). The reaction was monitored by TLC. After 3 h, the reaction was quenched with saturated aqueous NaHCO_3 solution and extracted with CH_2Cl_2 . The combined organic layers were washed with H_2O and brine successively, dried (MgSO_4), filtered, and concentrated. The residue was chromatographed (EtOAc) to afford **5** (5.63 g, 95%) as a pale yellow syrup: $[\alpha]_{\text{D}}^{20} -78.5$ (c 0.95, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 1.68–1.78 (m, 2H), 2.43 (s, 3H), 2.87 (dd, $J=13.2, 8.4$ Hz, 1H), 3.17 (dd, $J=13.5, 3.3$ Hz, 1H), 3.26 (dd, $J=10.5, 1.5$ Hz, 1H), 3.40 (dd, $J=10.2, 4.2$ Hz, 1H), 3.80 (s, 3H), 3.93–3.97 (m, 1H), 4.02–4.08 (m, 1H), 6.83 (dd, $J=8.7, 1.2$ Hz, 2H), 7.16 (dd, $J=8.7, 1.2$ Hz, 2H), 7.33 (d, $J=8.1$ Hz, 2H), 7.78 (d, $J=8.1$ Hz, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ 21.5, 39.2, 41.0, 55.1, 56.8, 60.0, 69.3, 113.7, 127.7, 128.3, 129.6, 130.7, 134.3, 143.6, 158.2; EIMS: m/z (%)=240 (100), 91 (38), 155 (36), 121 (19), 68 (7), 361 (1) $[\text{M}]^+$; Anal. Calcd for $\text{C}_{19}\text{H}_{23}\text{NO}_4\text{S}$: C 63.13, H 6.41, N 3.88; found C 63.25, H, 6.41, N 4.00.

4.1.3. Compound 6. A mixture of **5** (105 mg, 0.290 mmol) and IBX (*o*-iodoxybenzoic acid) (656 mg, 2.34 mmol) in EtOAc (20 mL) was refluxed for 9 h and the solid mass was filtered off. The filtrate was concentrated to give a residue, which was chromatographed (petroleum ether/EtOAc, 3:1) to afford **6** (102 mg, 98%) as a colorless solid: mp 98–99 °C; $[\alpha]_{\text{D}}^{20} +61.1$ (c 0.94, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 2.25 (d, $J=7.8$ Hz, 2H), 2.44 (s, 3H), 2.87 (AB part of ABX, $J_{\text{AB}}=13.2, J_{\text{AX}}=8.1, J_{\text{BX}}=3.3$ Hz, 2H), 3.55 (AB, $J_{\text{AB}}=18.6$ Hz, 2H), 3.79 (s, 3H), 4.44–4.49 (m, 1H), 6.81 (d, $J=8.1$ Hz, 2H), 7.09 (d, $J=8.1$ Hz, 2H), 7.33 (d, $J=8.1$ Hz, 2H), 7.73 (d, $J=8.1$ Hz, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ 21.5, 40.9, 41.5, 53.1, 55.1, 58.5, 114.0, 127.1, 127.7, 130.0, 130.7, 134.8, 144.1, 158.6, 209.2; EIMS: m/z (%)=182 (100), 181 (61), 155 (32), 91 (31), 238 (24), 359 (3) $[\text{M}]^+$; Anal. Calcd for $\text{C}_{19}\text{H}_{21}\text{NO}_4\text{S}$: C 63.49, H 5.89, N 3.90; found C 63.48, H 5.90, N 3.74.

4.1.4. Compound 7. To a solution of methylmagnesium iodide [prepared from methyl iodide (0.80 mL, 13 mmol)] in anhydrous Et_2O (20 mL) was added dropwise a solution of **6** (655 mg, 1.82 mmol) in anhydrous THF (10 mL). The reaction mixture was refluxed for 24 h and then quenched with saturated aqueous NH_4Cl solution. After removal of organic solvents, the residue was extracted with CH_2Cl_2 . The combined extracts were washed with distilled H_2O and brine successively, dried (MgSO_4), filtered, and concentrated. The residue was chromatographed (hexanes/EtOAc, 1:1) to afford **7** (532 mg, 78%) as a syrup: ^1H NMR (300 MHz, CDCl_3) δ 1.07 (s, 2.4H), 1.18 (s, 0.6H), 1.52–1.84 (m, 2H), 1.79 (s, 1H), 2.41 (s, 0.6H), 2.43 (s, 2.4H), 3.07 (d, $J=10.5$ Hz, 1H), 3.18–3.27 (m, 2H), 3.33 (d, $J=10.2$ Hz, 1H), 3.74–3.78 (m, 1H), 3.75 (s, 3H), 6.85 (d, $J=8.1$ Hz, 2H), 7.19 (d, $J=8.1$ Hz, 2H), 7.34 (d, $J=8.1$ Hz, 2H), 7.76 (d, $J=8.1$ Hz, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ (for the major epimer) 21.5, 25.4, 41.1, 43.0, 55.2, 61.5, 61.6, 75.9, 113.9, 127.6, 129.7, 130.0, 130.9, 133.7, 143.7, 158.2; δ (for the minor epimer) 21.5, 24.1, 40.9, 45.4, 55.2, 61.0, 61.6, 75.9, 113.7, 127.7, 129.6, 130.0, 130.6, 133.7, 143.7, 158.2; EIMS: m/z (%)=254 (100), 91 (46), 155 (27), 121 (23), 255 (16), 375 (0.4) $[\text{M}]^+$; Anal. Calcd

for $\text{C}_{20}\text{H}_{25}\text{NO}_4\text{S}$: C 63.97, H 6.71, N 3.73; found C 64.08, H 6.97, N 3.50.

4.1.5. Compound 8. Compound **7** (532 mg, 1.42 mmol) and pulverized AlCl_3 (3.20 g, 24.0 mmol) were mixed in anhydrous CH_2Cl_2 (35 mL). The mixture was stirred at room temperature for 8 h and then quenched with saturated aqueous NaHCO_3 solution. The organic phase was washed with distilled H_2O and brine successively, dried (MgSO_4), filtered and concentrated. The residue was purified by column chromatography (hexanes/EtOAc, 10:1) to afford **8** as a colorless solid. Recrystallization from petroleum ether/EtOAc afforded pure **8** (327 mg, 64%) as colorless needles: mp 161–162 °C. $[\alpha]_{\text{D}}^{20} -14.3$ (c 0.93, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 1.42 (s, 3H), 1.45–1.49 (m, 1H), 1.80 (d, $J=11.1$ Hz, 1H), 2.43 (s, 3H), 2.94 (d, $J=16.8$ Hz, 1H), 3.02 (dd, $J=9.0, 2.4$ Hz, 1H), 3.13 (d, $J=16.2$ Hz, 1H), 3.41 (dd, $J=9.0, 1.2$ Hz, 1H), 3.79 (s, 3H), 4.37–4.41 (m, 1H), 6.71–6.80 (m, 2H), 6.99 (d, $J=8.4$ Hz, 1H), 7.27 (d, $J=8.4$ Hz, 2H), 7.71 (d, $J=8.4$ Hz, 2H); EIMS: m/z (%)=173 (100), 174 (56), 357 (30) $[\text{M}]^+$, 91 (25), 159 (25).

4.1.6. Compound 9. To a solution of (2*S*,4*R*)-4-hydroxyproline (**2**, 10 g, 0.076 mol) in cold aqueous NaOH solution (1.0 M, 200 mL, 0.20 mol) was added freshly distilled BzCl (12 mL, 0.10 mol) in Et_2O (200 mL). The mixture was stirred for 24 h and the ether layer was then separated off. The aqueous layer was washed with Et_2O , cooled in an ice-bath, and acidified with hydrochloric acid. The solid was collected by filtration, washed with several portions of Et_2O to remove residual benzoic acid, and dried to provide **9** (13.55 g, 76%) as a colorless solid: mp 192–194 °C; $[\alpha]_{\text{D}}^{26} -135.8$ (c 1.38, EtOH); ^1H NMR (300 MHz, D_2O) δ 2.10–2.21 (m, 1H), 2.41 (dd, $J=13.8, 7.8$ Hz, 1H), 3.43 (d, $J=12.3$ Hz, 1H), 3.80 (dd, $J=12.0, 3.0$ Hz, 1H), 4.40–4.46 (m, 1H), 4.66 (dd, $J=9.6, 8.4$ Hz, 1H), 7.38–7.53 (m, 5H).

4.1.7. Compound 10. A mixture of **9** (3.00 g, 12.8 mmol) and acetic anhydride (22 mL) was heated at 90 °C under nitrogen for 5 h, cooled to room temperature, concentrated, and taken up in dichloromethane. The organic phase was washed with cold water, dried (Na_2SO_4), and concentrated. The residue was chromatographed (petroleum ether/EtOAc, 2:5) to yield **10** (2.5 g, 90%) as a colorless solid: mp 128–130 °C; $[\alpha]_{\text{D}}^{25} -93.0$ (c 1.14, EtOH); ^1H NMR (300 MHz, CDCl_3) δ 2.11 (dd, $J=10.8, 1.2$ Hz, 1H), 2.29 (d, $J=10.5$ Hz, 1H), 3.60–3.80 (m, 1H), 3.80 (d, $J=10.2$ Hz, 1H), 4.60 (br s, 1H), 5.24 (br s, 1H), 7.40–7.55 (m, 3H), 7.63 (d, $J=7.2$ Hz, 2H).

4.1.8. Compound 11. To a solution of (2*S*,4*R*)-4-hydroxyproline (**2**, 5.0 g, 38 mmol) in water (40 mL) were added Na_2CO_3 (8.5 g, 80 mmol) at 0 °C. Then *p*-toluenesulfonyl chloride (8.73 g, 45.8 mmol) was added in several portions over a period of 20 min. The slurry was then warmed to room temperature and allowed to stir for 48 h. The reaction mixture was acidified with concentrated HCl solution to pH 2 and the crude product was isolated via filtration. The filter cake was washed with 0.01 M HCl solution and dried in vacuum oven at 60 °C for 12 h to yield **11** (9.01 g, 83%) as a colorless solid: mp 149–151 °C; ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 1.90–2.00 (m, 2H), 2.39 (s, 3H), 3.08 (d,

$J=10.8$ Hz, 1H), 3.45 (dd, $J=9.9$, 3.3 Hz, 1H), 4.04 (t, $J=8.1$ Hz, 1H), 4.15–4.30 (m, 1H), 4.84 (s, 1H), 7.40 (d, $J=7.5$ Hz, 2H), 7.69 (d, $J=7.8$ Hz, 2H), 12.71 (s, 1H).

4.1.9. Compound 12. A mixture of **11** (350 mg, 1.23 mmol) and acetic anhydride (2 mL) was heated at 90 °C under nitrogen for 8 h, cooled to room temperature, concentrated, and the residual acetic anhydride was neutralized with saturated aqueous NaHCO₃ solution. The mixture was acidified with HCl solution to pH 2 and extracted with CH₂Cl₂/IPA (3:1). The combined organic layers were dried (MgSO₄), filtered, and concentrated. The residue was chromatographed (EtOAc/MeOH, 4:1) to yield **12** (382 mg, 95%) as a colorless solid: mp 55–57 °C; $[\alpha]_D^{25} -76.4$ (c 1.38, CHCl₃); ¹H NMR (300 MHz, DMSO-*d*₆) δ 1.50 (s, 3H), 2.06–2.16 (m, 1H), 2.24 (dd, $J=14.4$, 7.5 Hz, 1H), 2.40 (s, 3H), 3.36 (d, $J=12.9$ Hz, 1H), 3.64 (dd, $J=12.9$, 3.9 Hz, 1H), 4.06 (dd, $J=9.6$, 7.2 Hz, 1H), 5.02 (s, 1H), 7.46 (d, $J=7.8$ Hz, 2H), 7.71 (d, $J=7.8$ Hz, 2H), 12.94 (br s, 1H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 19.7, 20.5, 35.7, 53.5, 59.5, 72.2, 127.1, 129.3, 133.6, 143.2, 169.1, 172.5; ESI-MS: m/z (%)=328 (100) [M+H]⁺, 345 (15) [M+NH₄]⁺, 350 (28) [M+Na]⁺. HRMS (MALDI): calcd for C₁₄H₁₈NO₆S [M+H]⁺ 328.0855; found 328.0849.

4.1.10. Compounds 13, 14 and 15 (from 10). A solution of 4-methoxyphenylmagnesium bromide (0.278 M, 19.0 mL, 5.28 mmol), prepared from 4-bromoanisole and Mg in THF, was added to a mixture of **10** (300 mg, 1.38 mmol) and Me(MeO)NH·HCl (162 mg, 1.66 mmol) in THF (18 mL) under nitrogen at –78 °C. The mixture was stirred at –78 °C for 10 h, quenched with saturated aqueous NH₄Cl solution, and extracted with EtOAc. The combined organic layers were dried (MgSO₄), filtered, and concentrated. The residue was chromatographed (petroleum ether/EtOAc, 1:1, 1:2 then 0:1) to afford sequentially **15** (26 mg, 4%), **14** (187 mg, 41%), and **13** (212 mg, 55%) as colorless solids. Compound **15**: mp 146–148 °C; $[\alpha]_D^{25} -71.8$ (c 0.97, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 1.84–1.93 (m, 1H), 2.30–2.41 (m, 1H), 3.10–3.30 (m, 2H), 3.55–3.67 (m, 1H), 3.71 (s, 3H), 3.83 (s, 3H), 4.15–4.30 (m, 1H), 5.15–5.25 (m, 1H), 5.44–5.55 (m, 1H), 6.76 (d, $J=6.6$ Hz, 2H), 6.92 (d, $J=9.0$ Hz, 2H), 7.22–7.50 (m, 9H). ESI-MS: m/z (%)=416 (100) [M–OH]⁺, 456 (39) [M+Na]⁺; Anal. Calcd for C₂₆H₂₇NO₅: C 72.04, H 6.28, N 3.23; found C 71.84, H 6.26, N 3.11. Compound **13**: mp 126–128 °C; $[\alpha]_D^{24} -150.3$ (c 1.23, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 2.02 (d, $J=10.8$ Hz, 1H), 2.34–2.44 (m, 1H), 3.30 (s, 3H), 3.71 (s, 2H), 3.94 (s, 3H), 4.32 (d, $J=10.5$ Hz, 1H), 5.18 (s, 1H), 5.24 (d, $J=10.2$ Hz, 1H), 7.36–7.45 (m, 3H), 7.51–7.54 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 32.2, 36.7, 55.0, 59.0, 61.2, 71.3, 127.0, 128.2, 130.1, 135.8, 169.9, 173.6; ESI-MS: m/z (%)=218 (100) [M–N(MeO)Me]⁺, 279 (20) [M+H]⁺, 301 (93) [M+Na]⁺; HRMS (MALDI): calcd for C₁₄H₁₈N₂O₄Na [M+Na]⁺ 301.1164; found 301.1159. Compound **14**: mp 152–154 °C; $[\alpha]_D^{28} -162.9$ (c 0.87, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 2.0 (d, $J=13.8$ Hz, 1H), 2.38–2.48 (m, 1H), 3.76 (s, 2H), 3.87 (s, 3H), 4.30–4.40 (m, 1H), 4.46 (d, $J=10.5$ Hz, 1H), 5.70 (d, $J=9.6$ Hz, 1H), 6.97 (d, $J=8.4$ Hz, 2H), 7.38–7.45 (m, 3H), 7.53 (d, $J=6.3$ Hz, 2H), 8.12 (d, $J=7.8$ Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 36.8, 55.5, 57.9, 59.4, 70.8, 113.9, 127.3, 128.0, 128.2, 130.3, 131.1, 135.4, 164.0, 169.3,

198.0; ESI-MS: m/z (%)=326 (100) [M+H]⁺, 348 (64) [M+Na]⁺, 673 (34) [2M+Na]⁺; Anal. Calcd for C₁₉H₁₉NO₄: C 70.14, H 5.89, N 4.31; found C 70.00, H 5.89, N 4.14.

4.1.11. Compound 14 (from 13). A solution of 4-methoxyphenylmagnesium bromide (0.275 M, (7.5+12) mL, 5.36 mmol), prepared from 4-bromoanisole and Mg in THF, was added to a solution of **13** (212 mg, 0.762 mmol) in THF (7 mL) at –35 °C. The mixture was warmed gradually to room temperature, stirred at that temperature for 4 h, quenched with saturated aqueous NH₄Cl solution, concentrated, and extracted with EtOAc. The combined organic layers were washed with brine, dried (MgSO₄), filtered, and concentrated to give a residue, which was chromatographed (petroleum ether/EtOAc, 1:2) to afford **14** (159 mg, 64%) as a colorless solid.

4.1.12. Compound 16. A mixture of **14** (4.20 g, 12.9 mmol), 1,2-ethanedithiol (4.4 mL, 52 mmol), and BF₃·OEt₂ (0.66 mL, 5.2 mmol) in dry CH₂Cl₂ (110 mL) was refluxed for 4 days. The reaction mixture was quenched with saturated aqueous NaHCO₃ solution and extracted with CH₂Cl₂. The combined organic layers were washed with brine, dried (MgSO₄), filtered, and concentrated. The residue was chromatographed (petroleum ether/EtOAc, 3:2) to yield **16** (4.17 g, 80%) as a colorless solid: mp 168–170 °C; $[\alpha]_D^{25} +68.0$ (c 0.92, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 1.75–1.85 (m, 1H), 2.36–2.50 (m, 1H), 2.61 (d, $J=6.6$ Hz, 1H), 3.02–3.10 (m, 3H), 3.26–3.34 (m, 2H), 3.55–3.65 (m, 1H), 3.79 (s, 3H), 3.95–4.08 (m, 1H), 5.30 (t, $J=7.5$ Hz, 1H), 6.84 (d, $J=8.4$ Hz, 2H), 7.33–7.45 (m, 3H), 7.49 (d, $J=6.6$ Hz, 2H), 7.78 (d, $J=8.4$ Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 38.2, 38.3, 38.5, 55.2, 57.7, 62.5, 69.2, 80.1, 112.8, 128.1, 128.2, 130.0, 130.8, 134.5, 135.5, 158.8, 171.7; ESI-MS m/z (%)=402 (100) [M+H]⁺, 424 (16) [M+Na]⁺. HRMS (MALDI): calcd for C₂₁H₂₃NO₃S₂Na [M+Na]⁺ 424.1017; found 424.1012.

4.1.13. Compound 17 from 16. To a stirred solution of **16** (4.03 g, 10.0 mmol) in dry toluene (100 mL) maintained at 90 °C under argon was added a solution of tributyltin hydride (11.0 mL, 40.9 mmol) and AIBN (660 mg, 4.02 mmol) in toluene (25 mL). The reaction mixture was stirred for 2.5 h, cooled to room temperature, quenched with saturated aqueous NaHCO₃ solution, and extracted with EtOAc. The combined organic layers were washed with brine, dried (MgSO₄), filtered, and concentrated. The residue was chromatographed (petroleum ether/EtOAc, 3:2 then 1:2) to provide recovered **16** (617 mg, 15%) and **17** (2.26 g, 73%; or 86% brsm). Compound **17**, a colorless solid: mp 70–72 °C; $[\alpha]_D^{26} +95.7$ (c 0.91, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 1.70–2.20 (m, 2H), 2.55–3.05 (m, 1.5H), 3.08–3.24 (m, 1.5H), 3.50–3.60 (m, 1H), 3.78 (s, 3H), 4.00–4.30 (m, 1H), 4.40–4.60 (m, 1H), 6.55–6.70 (m, 1H), 6.87 (d, $J=8.1$ Hz, 1.5H), 7.20 (d, $J=7.8$ Hz, 1.5H), 7.35–7.50 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 37.0, 37.8, 55.1, 57.0, 57.6, 69.2, 113.6, 126.2, 127.1, 128.1, 130.1, 130.6, 136.4, 158.0, 170.0; ESI-MS m/z (%)=312 (100) [M+H]⁺, 333 (73) [M+Na–H], 366 (15) [M+MeOH+Na]⁺, 645 (21) [2M+Na]⁺; HRMS (EI): calcd for C₁₉H₂₁NO₃ 311.1521; found 311.1518.

4.1.14. Compound 17 from 14. To a stirred solution of **14** (150 mg, 0.461 mmol) in trifluoroacetic acid (3 mL) at 0 °C was added Et₃SiH (0.60 mL, 3.8 mmol). The mixture was stirred at room temperature for 36 h. After removal of most of the solvent, the residue was quenched with saturated aqueous NaHCO₃ solution and extracted with EtOAc. The combined organic layers were washed with brine, dried (MgSO₄), filtered, and concentrated. The residue was chromatographed (petroleum ether/EtOAc, 1.5:1 then 1:2) to give sequentially **17** (89 mg, 62% or 71% brsm) as a colorless solid, **14** (19 mg, 13%).

4.1.15. Compound 17 from 18. To a stirred solution of **18** (150 mg, 0.458 mmol) in trifluoroacetic acid (3 mL) at 0 °C was added Et₃SiH (0.60 mL, 3.8 mmol). The mixture was stirred at room temperature for 3 h. Standard work-up and chromatography by the procedure described for the conversion of **14** to **17** gave **17** (107 mg, 75%).

4.1.16. Compound 17 from 19. To a stirred solution of **19** (41 mg, 0.13 mmol) in trifluoroacetic acid (1 mL) at 0 °C was added Et₃SiH (0.17 mL, 1.1 mmol). The mixture was stirred at room temperature for 18.5 h. Standard work-up and chromatography by the procedure described for the conversion of **14** to **17** gave **17** (25 mg, 61%).

4.1.17. Compound 18. To a solution of **14** (240 mg, 0.738 mmol) in MeOH (5 mL) at 0 °C was added NaBH₄ (110 mg, 2.91 mmol). The reaction mixture was stirred at this temperature for 1 h, and then acetone was added to quench the excess NaBH₄. The mixture was concentrated, diluted with saturated aqueous NH₄Cl solution, and extracted with EtOAc. The combined organic layers were washed with brine, dried (MgSO₄), filtered, and concentrated. The residue was chromatographed (petroleum ether/EtOAc, 1:2) to give **18** (212 mg, 88%) as a colorless solid: mp 70–72 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.51–1.59 (m, 1H), 1.81–1.90 (m, 1H), 3.23–3.36 (m, 2H), 3.56 (dd, *J*=11.4, 6.0 Hz, 1H), 3.77 (s, 3H), 4.08 (dd, *J*=11.1, 5.4 Hz, 1H), 4.62 (dd, *J*=13.8, 7.5 Hz, 1H), 4.89 (d, *J*=7.5 Hz, 1H), 5.67 (s, 1H), 6.85 (d, *J*=8.4 Hz, 2H), 7.30 (d, *J*=8.4 Hz, 2H), 7.36–7.46 (m, 5H); ¹³C NMR (125 MHz, CDCl₃) δ 36.2, 55.1, 57.9, 63.3, 68.7, 77.7, 113.6, 126.9, 128.2, 130.3, 133.7, 135.7, 159.0, 173.0, 229.5; ESI-MS *m/z* (%)=310 (93) [M–OH]⁺, 350 (100) [M+Na]⁺, 382 (29) [M+MeOH+Na]⁺, 677 (80) [2M+Na]⁺; HRMS (ED): calcd for C₁₉H₁₉NO₃ [M–H₂O] 309.1365; found 309.1373. A small amount of the epimer of **18** (as the minor product) was also isolated. *epi-18*: ¹H NMR (300 MHz, CDCl₃) δ 1.97–2.10 (m, 2H), 3.50–3.58 (m, 2H), 3.82 (s, 3H), 4.20–4.27 (m, 1H), 4.60–4.67 (m, 1H), 5.52–5.58 (m, 1H), 6.91 (d, *J*=8.1 Hz, 2H), 7.33–7.52 (m, 7H); ESI-MS *m/z* (%)=310 (100) [M–OH]⁺, 328 (41) [M+H]⁺.

4.1.18. Compound 19. (a) *From 18 in the presence of BF₃·OEt₂ and Et₃SiH:* a mixture of **18** (113 mg, 0.345 mmol) and Et₃SiH (0.44 mL, 2.76 mmol) in CH₂Cl₂ (18 mL) was cooled in an ice/salt bath to 0 °C. To this cooled solution was added slowly BF₃·OEt₂ (0.32 mL, 2.5 mmol). When the reaction reached completion as judged by TLC, the mixture was quenched with saturated aqueous NaHCO₃ solution and extracted with CH₂Cl₂. The combined organic

layers were washed with brine, dried (MgSO₄), filtered, and concentrated. The residue was chromatographed (petroleum ether/EtOAc, 1:1) to give **19** (88 mg, 82%) as a colorless oil, rotamers (1.3:1): [α]_D²⁵ –157.9 (*c* 1.37, CHCl₃). Major rotamer: ¹H NMR (300 MHz, CDCl₃) δ 1.61 (d, *J*=10.2 Hz, 1H), 1.82 (d, *J*=10.2 Hz, 1H), 3.66 (s, 2H), 3.72 (s, 3H), 4.22 (s, 1H), 4.84 (s, 1H), 5.12 (s, 1H), 6.81 (d, *J*=8.7 Hz, 2H), 7.02 (d, *J*=8.4 Hz, 2H), 7.40–7.53 (m, 3H), 7.53–7.62 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 33.1, 55.1 (probably corresponding to two types of carbon), 65.2, 76.1, 84.6, 113.7, 126.0, 126.9, 128.5, 130.2, 131.5, 136.2, 158.9, 169.0. Minor rotamer: ¹H NMR (300 MHz, CDCl₃) δ 1.67 (d, *J*=10.5 Hz, 1H), 1.93 (d, *J*=9.9 Hz, 1H), 3.47 (s, 2H), 3.76 (s, 3H), 4.71 (s, 1H), 4.87 (s, 1H), 5.16 (s, 1H), 6.88 (d, *J*=8.4 Hz, 2H), 7.29 (d, *J*=8.7 Hz, 2H), 7.40–7.53 (m, 3H), 7.53–7.62 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 31.5, 53.5, 57.3, 61.6, 76.3, 84.0, 113.6, 126.4, 127.2, 128.2, 130.3, 132.1, 135.7, 158.8, 170.1; ESI-MS *m/z* (%)=310 (100) [M+H]⁺, 332 (17) [M+Na]⁺, 350 (12) [M+NH₄+Na]⁺, 364 (43) [M+MeOH+Na]⁺, 641 (35) [2M+Na]⁺; Anal. Calcd for C₁₉H₁₉NO₃: C 73.77, H 6.19, N 4.53; found C 73.63, H 6.30, N 4.47.

(b) *From 18 in the presence of TFA:* a stirred solution of **18** (100 mg, 0.305 mmol) in trifluoroacetic acid (3 mL) was stirred at room temperature for 6.5 h. Standard work-up and chromatography by the procedure described above gave **19** (32 mg, 34%).

4.1.19. Compound 20. To a suspension of LiAlH₄ (29 mg, 0.763 mmol) in THF (4 mL) at room temperature was added a solution of **19** (59 mg, 0.19 mmol) in THF (6 mL). The mixture was refluxed for 30 min and then cooled to room temperature. A small quantity of Na₂SO₄ solid and several drops of H₂O were added to the reaction mixture. The solid mass was filtered off and the filtrate was concentrated to give a residue, which was chromatographed (petroleum ether/EtOAc, 2:1) to give **20** (43 mg, 76%) as a pale yellow oil: [α]_D²⁶ –104.9 (*c* 0.87, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 1.66 (dd, *J*=10.2, 2.1 Hz, 1H), 1.75 (d, *J*=9.9 Hz, 1H), 2.69 (d, *J*=9.9 Hz, 1H), 2.98 (dd, *J*=9.6, 1.2 Hz, 1H), 3.35 (s, 1H), 3.79 (s, 3H), 3.94 (dd, *J*=20.7, 12.3 Hz, 2H), 4.60 (s, 1H), 5.24 (s, 1H), 6.86 (d, *J*=8.7 Hz, 2H), 7.15 (d, *J*=8.7 Hz, 2H), 7.25–7.50 (m, 5H); ¹³C NMR (75 MHz, CDCl₃) δ 31.6, 55.1, 57.3, 59.8, 66.9, 77.5, 78.9, 113.4, 126.2, 127.0, 128.3, 128.5, 133.8, 139.3, 158.3; ESI-MS *m/z* (%)=296 (100) [M+H]⁺; HRMS (MALDI): calcd for C₁₉H₂₂NO₂ [M+H]⁺ 296.1651; found 296.1645.

4.1.20. Compound 21. To a solution of (COCl)₂ (78 μL, 0.91 mmol) in CH₂Cl₂ (5 mL) was added dropwise a solution of DMSO (0.13 mL, 1.8 mmol) in CH₂Cl₂ (3 mL) at –78 °C. The mixture was stirred at –78 °C for 10 min and a solution of **17** (70 mg, 0.22 mmol) in CH₂Cl₂ (3 mL) was added. The mixture was stirred at –78 °C for 30 min and Et₃N (0.38 mL, 2.7 mmol) was added. The reaction mixture was allowed to warm to room temperature. Standard work-up and evaporation gave a residue, which was chromatographed (petroleum ether/EtOAc, 2:1) to afford **21** (68 mg, 98%) as a pale yellow solid: mp 98–100 °C; [α]_D²⁷ +8.2 (*c* 1.14, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 2.40–3.10

(m, 4H), 3.40–3.80 (m, 2H), 3.78 (s, 3H), 4.10–5.35 (m, 1H), 6.71–7.22 (m, 4H), 7.37–7.52 (m, 5H); ESI-MS m/z (%)=310 (85) $[M+H]^+$, 332 (56) $[M+Na]^+$, 364 (100) $[M+MeOH+Na]^+$; Anal. Calcd for $C_{19}H_{19}NO_3$: C 73.77, H 6.19, N 4.53; found C 73.93, H 6.24, N 4.32.

4.1.21. Compound 22. A solution of MeLi (1.0 M, 1.20 mL, 1.20 mmol) was added dropwise to a solution of **21** (277 mg, 0.895 mmol) in anhydrous THF (15 mL) at -78°C . After 2 h, the mixture was quenched with saturated aqueous NH_4Cl solution, concentrated, and extracted with EtOAc. The combined organic layers were washed with brine, dried ($MgSO_4$), filtered, and concentrated. The residue was chromatographed (petroleum ether/EtOAc, 5:2 then 3:2) to afford recovered **21** (143 mg, 52%) and **22** (113 mg, 39%; or 80% brsm). Compound **22**, a colorless solid: mp 121–123 $^\circ\text{C}$; $[\alpha]_D^{27} +107.9$ (c 0.85, $CHCl_3$); 1H NMR (300 MHz, $CDCl_3$) δ 1.21 (s, 2.5H), 1.44 (s, 0.5H), 1.91 (d, $J=7.2$ Hz, 2H), 2.26 (s, 1H), 2.96–3.10 (m, 1H), 3.13–3.35 (m, 2.5H), 3.70–3.82 (m, 0.5H), 3.79 (s, 3H), 4.00–4.15 (m, 0.17H), 4.40–4.50 (m, 0.83H), 6.56–6.77 (m, 0.66H), 6.85 (d, $J=7.2$ Hz, 1.67H), 7.18 (d, $J=7.8$ Hz, 1.67H), 7.38–7.45 (m, 3H), 7.45–7.55 (m, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 26.2, 37.7, 42.8, 55.1, 58.1, 62.2, 75.1, 113.7, 126.3, 127.2, 128.2, 130.1, 130.7, 136.5, 158.1, 170.2; ESI-MS m/z (%)=326 (100) $[M+H]^+$, 348 (39) $[M+Na]^+$, 380 (8) $[M+MeOH+Na]^+$; Anal. Calcd for $C_{20}H_{23}NO_3$: C 73.82, H 7.12, N 4.30; found C 73.95, H 7.11, N 4.17.

4.1.22. Compound 23. $AlCl_3$ (4.14 g, 31.0 mmol) was added to a solution of **22** (0.718 g, 2.21 mmol) in dry CH_2Cl_2 (45 mL). The mixture was stirred at room temperature for 27 h and poured into saturated aqueous $NaHCO_3$ solution. The solid mass was filtered off and the two layers of the filtrate were separated. The aqueous layer was extracted with CH_2Cl_2 . The combined organic layers were washed successively with water and brine, dried ($MgSO_4$), filtered, and concentrated. The residue was chromatographed (petroleum ether/EtOAc, 3:1) to give **23** (513 mg, 76%) as a colorless oil: $[\alpha]_D^{28} +76.2$ (c 1.53, $CHCl_3$); 1H NMR (300 MHz, $CDCl_3$) δ 1.48 (s, 2H), 1.59 (s, 1H), 1.90–2.10 (m, 2H), 2.81 (s, 0.67H), 2.98 (dd, $J=17.1$, 2.4 Hz, 0.67H), 3.30–3.54 (m, 2.66H), 3.76 (s, 2H), 3.80 (s, 1H), 4.32–4.37 (m, 0.33H), 4.85–4.91 (m, 0.67H), 6.70–6.80 (m, 1.65H), 6.86 (d, $J=2.4$ Hz, 0.35H), 6.97 (d, $J=8.4$ Hz, 0.35H), 7.07 (d, $J=8.4$ Hz, 0.65H), 7.30–7.37 (m, 3.25H), 7.41–7.48 (m, 1.75H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 20.6, 20.8, 34.8, 37.3, 40.0, 41.0, 41.9, 42.2, 54.7, 54.9, 55.0, 56.4, 61.5, 64.1, 109.4, 109.5, 111.4, 111.5, 124.0, 125.3, 126.1, 126.5, 127.8, 128.1, 129.1, 129.2, 129.9, 130.2, 136.7, 137.2, 144.7, 145.6, 157.5, 157.9, 168.7, 169.8; ESI-MS m/z (%)=308 (100) $[M+H]^+$, 330 (6) $[M+Na]^+$, 362 (19) $[M+MeOH+Na]^+$; HRMS (EI): calcd for $C_{20}H_{21}NO_2$ 307.1572; found 307.1570.

4.1.23. Compound 24. To a solution of **23** (459 mg, 1.49 mmol) in ethanol (7 mL) was added 50% aqueous NaOH solution (7 mL). The mixture was refluxed for 24 h, cooled to room temperature, concentrated, neutralized with saturated aqueous NH_4Cl solution, and extracted with CH_2Cl_2/IPA (3:1). The combined organic layers were dried ($MgSO_4$), filtered, and concentrated. The residue was

chromatographed ($CH_2Cl_2/MeOH/Et_3N$, 100:10:1) to give the hydrolysis product.

A mixture of the above hydrolysis product, formalin (containing 37% CH_2O , 1.4 mL, 18 mmol), and $NaCNBH_3$ (95%, 990 mg, 15.0 mmol) in MeOH (18 mL) was stirred overnight at room temperature. After evaporation of the volatiles, the residue was partitioned between 5% HCl and ether, and the two layers were separated. The aqueous layer was washed one more time with ether and the organic layer was discarded. The aqueous layer was made basic with concentrated NH_4OH solution and extracted with CH_2Cl_2/IPA (3:1). The combined organic layers were dried ($MgSO_4$), filtered, and concentrated. The residue was chromatographed ($CH_2Cl_2/MeOH/Et_3N$, 100:2:1) to give (–)-aphanorphine methyl ether **24** (230 mg, 71% for two steps from **23**) as a colorless oil: $[\alpha]_D^{28} -10.38$ (c 1.36, $CHCl_3$); 1H NMR (300 MHz, $CDCl_3$) δ 1.46 (s, 3H, CH_3), 1.83 (d, $J=11.1$ Hz, 1H, 0.5 CH_2), 2.01 (dd, $J=11.1$, 6.0 Hz, 1H, 0.5 CH_2), 2.46 (s, 3H, NCH_3), 2.74 (d, $J=6.0$ Hz, 1H, 0.5 CH_2), 2.81 (s, 1H, 0.5 CH_2), 2.84 (s, 1H, 0.5 CH_2), 3.02 (d, $J=16.8$ Hz, 1H, 0.5 CH_2), 3.37–3.40 (m, 1H, NCH), 3.75 (s, 3H, OCH_3), 6.67 (dd, $J=8.4$, 2.1 Hz, 1H, CH), 6.77 (s, 1H, CH), 7.00 (d, $J=8.4$ Hz, 1H, CH); ^{13}C NMR (100 MHz, $CDCl_3$) δ 21.2, 35.3, 41.3, 41.4, 42.9, 54.9, 61.1, 71.0, 109.1, 110.8, 125.6, 129.9, 147.6, 157.5; EIMS m/z (%)=218 (18) $[M+H]^+$, 217 (48) $[M]^+$, 202 (100), 159 (64), 144 (28), 115 (38); HRMS (EI): calcd for $C_{14}H_{19}NO$ 217.1467; found 217.1460.

Acknowledgements

The financial support was provided by the grants from NSFC (20625204; 20632030), STCSM ('Post-Venus' Program, 05QMH1416), and GCCP of ECNU.

References and notes

- Gulavita, N.; Hori, A.; Shimizu, Y.; Laszlo, P.; Clardy, J. *Tetrahedron Lett.* **1988**, 29, 4381.
- (a) Takano, S.; Inomata, K.; Sato, T.; Ogasawara, K. *J. Chem. Soc., Chem. Commun.* **1989**, 1591; (b) Takano, S.; Inomata, K.; Sato, T.; Takahashi, M.; Ogasawara, K. *J. Chem. Soc., Chem. Commun.* **1990**, 290; (c) Honda, T.; Yamamoto, A.; Cui, Y. S.; Tsubuki, M. *J. Chem. Soc., Perkin Trans. 1* **1992**, 531; (d) Hume, A. N.; Henry, S. S.; Meyers, A. I. *J. Org. Chem.* **1995**, 60, 1265; (e) Meyers, A. I.; Schmidt, W.; Santiago, B. *Heterocycles* **1995**, 40, 525; (f) Fadel, A.; Arzel, P. *Tetrahedron: Asymmetry* **1995**, 6, 893; (g) Hallinan, K. O.; Honda, T. *Tetrahedron* **1995**, 51, 12211; (h) Node, M.; Imazato, H.; Kurosaki, R.; Kawano, Y.; Inoue, T.; Nishide, K. *Heterocycles* **1996**, 42, 811; (i) Shiotani, S.; Okada, H.; Nakamata, K.; Yamamoto, T.; Sekino, F. *Heterocycles* **1996**, 43, 1031; (j) Fadel, A.; Arzel, P. *Tetrahedron: Asymmetry* **1997**, 8, 283; (k) Fadel, A.; Arzel, P. *Tetrahedron: Asymmetry* **1997**, 8, 371; (l) Shimizu, M.; Kamikubo, T.; Ogasawara, K. *Heterocycles* **1997**, 46, 21; (m) Tamura, O.; Yangimachi, T.; Kobayashi, T.; Ishibashi, H. *Org. Lett.* **2001**, 3, 2427; (n) Fuchs, J. R.; Funk, R. L. *Org. Lett.* **2001**, 3, 3923; (o) Tanaka, K.; Taniguchi, T.; Ogasawara, K. *Tetrahedron Lett.* **2001**, 42, 1049; (p) El Azab, A. S.; Taniguchi, T.

- Ogasawara, K. *Heterocycles* **2002**, *56*, 39; (q) Kita, Y.; Futamura, J.; Ohba, Y.; Sawama, Y.; Ganesh, J. K.; Fujioka, H. *J. Org. Chem.* **2003**, *68*, 5917; (r) Zhai, H.; Luo, S.; Ye, C.; Ma, Y. *J. Org. Chem.* **2003**, *68*, 8268; (s) Hu, H.; Zhai, H. *Synlett* **2003**, 2129; (t) Taylor, S. K.; Ivanovic, M.; Simons, L. J.; Davis, M. M. *Tetrahedron: Asymmetry* **2003**, *14*, 743; (u) Tamura, O.; Yanagimachi, T.; Ishibashi, H. *Tetrahedron: Asymmetry* **2003**, *14*, 3033; (v) Katoh, M.; Inoue, H.; Suzuki, A.; Honda, T. *Synlett* **2005**, 2820; (w) Bower, J. F.; Szeto, P.; Gallagher, T. *Chem. Commun.* **2005**, 5793; (x) Li, M.; Zhou, P.; Roth, H. F. *Synthesis* **2007**, 55; (y) Ma, Z.; Zhai, H. *Synlett* **2007**, 161.
3. Shiotani, S.; Kometani, T.; Mitsunashi, K.; Nozawa, T.; Kurobe, A.; Futsukaichi, O. *J. Med. Chem.* **1976**, *19*, 803.
4. Palmer, D. C.; Strauss, M. J. *Chem. Rev.* **1977**, *77*, 1.
5. (a) Hanessian, S. *Total Synthesis of Natural Products: The 'Chiron' Approach*; Pergamon: Oxford, 1983; (b) Ho, T.-L. *Enantioselective Synthesis: Natural Products from Chiral Terpenes*; John Wiley and Sons: New York, NY, 1992; (c) Coppola, G. M.; Schuster, H. F. *Asymmetric Synthesis: Construction of Chiral Molecules Using Amino Acids*; John Wiley and Sons: New York, NY, 1987.
6. For the preparation of compound **3**, see: (a) Han, G.; LaPorte, M. G.; Folmer, J. J.; Werner, K. M.; Weinreb, S. M. *J. Org. Chem.* **2000**, *65*, 6293; (b) Westwood, N. B.; Walker, R. T. *Tetrahedron* **1998**, *54*, 13391.
7. (a) Anthory, J. M.; Debra, S. B.; Daniel, S. *J. Org. Chem.* **1979**, *44*, 4148; (b) More, J. D.; Finney, N. S. *Org. Lett.* **2002**, *4*, 3001.
8. Steele, M.; Watkinson, M.; Whiting, A. *J. Chem. Soc., Perkin Trans. 1* **2001**, 588.
9. For reduction with triethylsilane, see: (a) Orfanopoulos, M.; Smonou, I. *Synth. Commun.* **1988**, *18*, 833; (b) Smonou, I.; Orfanopoulos, M. *Tetrahedron Lett.* **1988**, *29*, 5793.
10. For methylation of similar pyrrolidinones, see: (a) Blanco, M.-J.; Sardina, F. J. *J. Org. Chem.* **1998**, *63*, 3411; (b) Moulines, J.; Bats, J.-P.; Hautefaye, P.; Nuhlich, A.; Lamidey, A.-M. *Tetrahedron Lett.* **1993**, *34*, 2315.
11. (a) Portoghese, P. S.; Turcotte, J. G. *Tetrahedron* **1971**, *27*, 961; (b) Croce, P. D.; Rosa, C. L. *Tetrahedron: Asymmetry* **2002**, *13*, 197.
12. Braish, T. F.; Fox, D. E. *J. Org. Chem.* **1990**, *55*, 1684.
13. Williams, J. M.; Jobson, R. B.; Yasuda, N.; Marchesini, G.; Dolling, U.-H.; Grabowski, E. J. *J. Tetrahedron Lett.* **1995**, *36*, 5461.
14. (a) Luo, S.; Zificsak, C. A.; Hsung, R. P. *Org. Lett.* **2003**, *5*, 4709; (b) Baussanne, I.; Schwardt, O.; Royer, J.; Pichon, M.; Figadere, B.; Cave, A. *Tetrahedron Lett.* **1997**, *38*, 2259.
15. West, C. T.; Donnelly, S. J.; Kooistra, D. A.; Doyle, M. P. *J. Org. Chem.* **1973**, *38*, 2675.
16. Huffman, J. W.; Yu, S. *Bioorg. Med. Chem.* **1998**, *6*, 2281.
17. Mäkelä, T.; Matikainen, J.; Wähälä, K.; Hase, T. *Tetrahedron* **2000**, *56*, 1873.
18. Barton, D. H. R.; Bielska, M. T.; Cardoso, J. M.; Cussans, N. J.; Ley, S. V. *J. Chem. Soc., Perkin Trans. 1* **1981**, 1840.
19. Albaugh, P. A.; Marshall, L.; Gregory, J.; White, G.; Hutchison, A.; Ross, P. C.; Gallagher, D. W.; Tallman, J. F.; Crago, M.; Cassella, J. V. *J. Med. Chem.* **2002**, *45*, 5043.